SecBot SecBot
SECBOTREPLAY Home › Report › STOK

STOK · Stoke Therapeutics filed a prospectus supplement to sell up to $200…

Stoke Therapeutics, Inc. · 8-K filed Aug 3, 2026 at 17:06 ET

At the news

BEARISHIMPACT 6/10

8-K filed Aug 3, 2026 at 17:06 ET

Stoke Therapeutics filed a prospectus supplement to sell up to $200 million of common stock in an at-the-market (ATM) offering through Cantor Fitzgerald. At a $1.8B market cap, this represents ~11% potential dilution, creating near-term selling pressure and a clear negative signal for existing shareholders.

  • On August 3, 2026, Stoke filed a prospectus supplement under its existing Sales Agreement with Cantor Fitzgerald for an ATM offering of up to $200 million in common stock.
  • The offering is made under the Company's automatic shelf registration statement on Form S-3ASR (File No. 333-294402) filed March 18, 2026.
  • Shares may be sold from time to time at market prices, with no fixed timetable or minimum price.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access